

# Das Reizdarmsyndrom: Update zur aktualisierten Leitlinie

## Teil 2: Therapie, RDS bei Kindern und Fazit

Sabine Poschwatta-Rupp

### eLiteratur

- e1. Ringel-Kulka T, McRorie J, Ringel Y: Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic *Bifidobacterium infantis* 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. *Am J Gastroenterol* 2017; 112: 145-51. (Abstract)
- e2. O'Mahony L, McCarthy J, Kelly P, et al.: *Lactobacillus* and *bifidobacterium* in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology* 2005; 128: 541-51.
- e3. Whorwell PJ, Altringer L, Morel J, et al.: Efficacy of an encapsulated probiotic *Bifidobacterium infantis* 35624 in women with irritable bowel syndrome. *Am J Gastroenterol* 2006; 101: 1581-90.
- e4. Charbonneau D, Gibb RD, Quigley EM: Fecal excretion of *Bifidobacterium infantis* 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. *Gut Microbes* 2013; 4: 201-11.
- e5. Pinto-Sanchez MI, Hall GB, Ghajar K, et al.: Probiotic *Bifidobacterium longum* NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. *Gastroenterology* 2017; 153: 448-59.e448.
- e6. Guyonnet D, Chassany O, Ducrotte P, et al.: Effect of a fermented milk containing *Bifidobacterium animalis* DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. *Aliment Pharmacol Ther* 2007; 26: 475-86.
- e7. Marteau P, Cuillerier E, Meance S, et al.: *Bifidobacterium animalis* strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. *Aliment Pharmacol Ther* 2002; 16: 587-93.
- e8. Guglielmetti S, Mora D, Gschwender M, Popp K: Randomised clinical trial: *Bifidobacterium bifidum* MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2011; 33: 1123-32.
- e9. Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S: Randomized clinical trial: effect of *Lactobacillus plantarum* 299 v on symptoms of irritable bowel syndrome. *Nutrition* 2014; 30: 1151-7.
- e10. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. *Am J Gastroenterol* 2000; 95: 1231-8.
- e11. Niedzielin K, Kordecki H, Birkenfeld B: A controlled, double-blind, randomized study on the efficacy of *Lactobacillus plantarum* 299V in patients with irritable bowel syndrome. *Eur J Gastroenterol Hepatol* 2001; 13: 1143-7.
- e12. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO: Effect of *Lactobacillus plantarum* 299v on colonic fermentation and symptoms of irritable bowel syndrome. *Dig Dis Sci* 2002; 47: 2615-20.
- e13. Ducrotte P, Sawant P, Jayanthi V: Clinical trial: *Lactobacillus plantarum* 299v (DSM 9843) improves symptoms of irritable bowel syndrome. *World J Gastroenterol* 2012; 18: 4012-8.
- e14. Fuke N, Aizawa K, Suganuma H, Takagi T, Naito Y: Effect of combined consumption of *Lactobacillus brevis* KB290 and beta-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial. *Int J Food Sci Nutr* 2017; 68: 973-86.
- e15. Murakami K, Habukawa C, Nobuta Y, Moriguchi N, Takemura T: The effect of *Lactobacillus brevis* KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial. *Biopsychosoc Med* 2012; 6: 16.
- e16. Lyra A, Hillila M, Huttunen T, et al.: Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. *World J Gastroenterol* 2016; 22: 10631-42.
- e17. Sinn DH, Song JH, Kim HJ, et al.: Therapeutic effect of *Lactobacillus acidophilus*-SDC 2012, 2013 in patients with irritable bowel syndrome. *Dig Dis Sci* 2008; 53: 2714-8.
- e18. Nobutani K, Sawada D, Fujiwara S, et al.: The effects of administration of the *Lactobacillus gasseri* strain CP2305 on quality of life, clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. *J Appl Microbiol* 2017; 122: 212-24.
- e19. Ojetti V, Ianiro G, Tortora A, et al.: The effect of *Lactobacillus reuteri* supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. *J Gastrointestin Liver Dis* 2014; 23: 387-91.
- e20. Niv E, Naftali T, Hallak R, Vaisman N: The efficacy of *Lactobacillus reuteri* ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study. *Clin Nutr* 2005; 24: 925-31.
- e21. Thijssen AY, Clemens CH, Vankerckhoven V, Goossens H, Jonkers DM, Masclee AA: Efficacy of *Lactobacillus casei* Shirota for patients with irritable bowel syndrome. *Eur J Gastroenterol Hepatol* 2016; 28: 8-14.
- e22. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ: Probiotic beverage containing *Lactobacillus casei* Shirota improves gastrointestinal symptoms in patients with chronic constipation. *Can J Gastroenterol* 2003; 17: 655-9.
- e23. Majeed M, Nagabhushanam K, Natarajan S, et al.: *Bacillus coagulans* MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. *Nutr J* 2016; 15: 21.
- e24. Dolin BJ: Effects of a proprietary *Bacillus coagulans* preparation on symptoms of diarrhea-predominant irritable bowel syndrome. *Methods Find Exp Clin Pharmacol* 2009; 31: 655-9.
- e25. Enck P, Zimmermann K, Menke G, Klosterhalfen S: Ran-

- domized controlled treatment trial of irritable bowel syndrome with a probiotic *E.-coli* preparation (DSM17252) compared to placebo. *Z Gastroenterol* 2009; 47: 209-14.
- e26. Abbas Z, Yakoob J, Jafri W, et al.: Cytokine and clinical response to *Saccharomyces boulardii* therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. *Eur J Gastroenterol Hepatol* 2014; 26: 630-9.
- e27. Pineton de Chambrun G, Neut C, Chau A, et al.: A randomized clinical trial of *Saccharomyces cerevisiae* versus placebo in the irritable bowel syndrome. *Dig Liver Dis* 2015; 47: 119-24.
- e28. Spiller R, Pelerin F, Cayzele Decherf A, et al.: Randomized double blind placebo-controlled trial of *Saccharomyces cerevisiae* CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. *United European Gastroenterol J* 2016; 4: 353-62.
- e29. Lorenzo-Zuniga V, Llop E, Suarez C, et al.: I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. *World J Gastroenterol* 2014; 20: 8709-16.
- e30. Ludidi S, Jonkers DM, Koning CJ, et al.: Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. *Neurogastroenterol Motil* 2014; 26: 705-14. (Abstract)
- e31. Sisson G, Ayis S, Sherwood RA, Bjarnason I: Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome—a 12 week double-blind study. *Aliment Pharmacol Ther* 2014; 40: 51-62.
- e32. Yoon JS, Sohn W, Lee OY, et al.: Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *J Gastroenterol Hepatol* 2014; 29: 52-9.
- e33. Choi CH, Kwon JG, Kim SK, et al.: Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. *Neurogastroenterol Motil* 2015; 27: 705-16.
- e34. Hod K, Sperber AD, Ron Y, et al.: A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. *Neurogastroenterol Motil* 2017; 29.
- e35. Jafari E, Vahedi H, Merat S, Momtahan S, Riahi A: Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. *Arch Iran Med* 2014; 17: 466-70.
- e36. Mezzasalma V, Manfrini E, Ferri E, et al.: A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation. *Biomed Res Int* 2016; 2016: 4740907.
- e37. Yoon H, Park YS, Lee DH, Seo JG, Shin CM, Kim N: Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. *J Clin Biochem Nutr* 2015; 57: 129-34.
- e38. Kim HJ, Vazquez Roque MI, Camilleri M, et al.: A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. *Neurogastroenterol Motil* 2005; 17: 687-96.
- e39. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al.: Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. *Aliment Pharmacol Ther* 2008; 27: 48-57.
- e40. Williams EA, Stimpson J, Wang D, et al.: Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. *Aliment Pharmacol Ther* 2009; 29: 97-103.